by Portfolio Grader | February 7, 2013 2:00 pm
For the current week, the overall ratings of six Life Science stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Agilent Technologies (NYSE:A) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Agilent Technologies serves the communications, electronics, life sciences, and chemical analysis industries by designing and producing bio-analytical and electronic measurement solutions. For a full analysis of A stock, visit Portfolio Grader.
Compugen (NASDAQ:CGEN) earns a D this week, falling from last week’s grade of C. Compugen focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The stock also rates an F in Equity. To get an in-depth look at CGEN, get Portfolio Grader’s complete analysis of CGEN stock.
This week, BG Medicin (NASDAQ:BGMD) drops from C to a D rating. BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that it identifies. The stock gets F’s in Equity, Cash Flow, and Sales Growth. The stock price has fallen 15.2% over the past month, worse than the 2.5% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BGMD stock.
Affymetrix (NASDAQ:AFFX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Affymetrix is involved in the development, manufacturing and sale of products and services for genetic analysis to the life science research and clinical healthcare markets. The stock also gets an F in Equity. As of Feb. 7, 2013, 15.2% of outstanding Affymetrix shares were held short. To get an in-depth look at AFFX, get Portfolio Grader’s complete analysis of AFFX stock.
This is a rough week for Sequenom Inc. (NASDAQ:SQNM). The company’s rating falls to D from the previous week’s C. Sequenom is a molecular diagnostic testing and genetics analysis company. The stock gets F’s in Equity and Cash Flow. As of Feb. 7, 2013, 31.6% of outstanding Sequenom Inc. shares were held short. For a full analysis of SQNM stock, visit Portfolio Grader.
Pacific Biosciences of California (NASDAQ:PACB) gets weaker ratings this week as last week’s D drops to an F. Pacific Biosciences of California has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. The stock gets F’s in Equity, Cash Flow, and Sales Growth. For more information, get Portfolio Grader’s complete analysis of PACB stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/02/6-life-science-stocks-to-sell-now-a-cgen-bgmd/
Short URL: http://investorplace.com/?p=303518
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.